In the AD literature, a relevant number of Phase I and Phase II studies has indicated that the CSF levels of biomarkers reflecting amyloid deposition (i.e., Aβ42) and neurodegeneration (i.e., T-tau and P-tau) are significantly different between subjects diagnosed with AD and to normal controls. This evidence concerns the gene MAPT and Alzheimer disease.